Adoptive T cell therapy for cancer in the clinic

Carl H. June

Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

The transfusion of lymphocytes, referred to as adoptive T cell therapy, is being tested for the treatment of cancer and chronic infections. Adoptive T cell therapy has the potential to enhance antitumor immunity, augment vaccine efficacy, and limit graft-versus-host disease. This form of personalized medicine is now in various early- and late-stage clinical trials. These trials are currently testing strategies to infuse tumor-infiltrating lymphocytes, CTLs, Th cells, and Tregs. Improved molecular biology techniques have also increased enthusiasm and feasibility for testing genetically engineered T cells. The current status of the field and prospects for clinical translation are reviewed herein.

Over the past 50 years, two fundamentally different strategies to stimulate antitumor immunity have been tested in humans: therapeutic vaccination and passive immunization. Passive immunization, herein referred to as adoptive T cell therapy, is the transfusion of autologous or allogeneic T cells into tumor-bearing hosts, i.e., patients. Evidence that T cells can help to control tumor growth has been provided by the analysis of tumor prevalence in immunodeficient mice and humans (1, 2). In the 1970s, Chester Southam and colleagues demonstrated that subcutaneous growth of human tumor autografts to patients bearing advanced cancers was inhibited by cotransfer of autologous leukocytes in about half of the patients (3). This suggested that leukocytes with a specific inhibitory effect on the implantation and growth of cancer cells were present in many patients with advanced cancer and could be used as potential candidates for adoptive immunotherapy. Furthermore, recent evidence indicates that tumor infiltration by human T cells is a powerful predictive biomarker of survival for ovarian and colorectal cancers (4, 5).

Therapeutic cancer vaccines are entering the realm of clinical medicine, but despite more than 60 years of research into this therapeutic approach (6), there are currently no FDA-approved adoptive T cell therapies for cancer. However, the recent explosion of knowledge in the fields of T cell and cancer biology has enabled new approaches that might bring adoptive T cell transfer to the routine practice of clinical medicine, with an impact similar to that of the advent of transfusion medicine, which was enabled by blood bank transfusion technology in the first half of the last century. The application of recent lessons from adoptive transfer in lymphodepleted hosts (7), the ability to overcome barriers presented by Tregs (8, 9), and the use of improved culture systems (10) have not yet been tested in randomized clinical trials. The intent of this review is on the use adoptive T cell therapy for cancer in the clinic is to focus on issues facing the field, with an emphasis on therapy with CTLS, tumor-infiltrating lymphocytes (TILs), engineered T cells, and the use of adoptive T cell transfers to facilitate therapeutic cancer vaccines.

CTL therapy

At present, there is a plethora of suitable CTL targets for many tumors (11). Improved CTL cell culture technology (12) has permitted the first clinical tests of adoptive transfer of CTLs, and the approach seems to result in substantial activity in patients with melanoma; CTLs derived from PBMs were used to treat patients with refractory, metastatic melanoma, and of the 20 patients had minor, mixed, or stable antitumor immune responses (13). Furthermore, the infusion of autologous melanoma-associated antigen recognized by T cells 1–specific (MART-1–specific) CD8+ T cells into a patient with metastatic melanoma resulted in T cell infiltration into both the skin and tumor tissue (14). The in vivo efficacy of the infused T cell population was indicated by the destruction of normal melanocytes and outgrowth of a MART-1–negative tumor, demonstrating the selection of a tumor variant with loss of MART-1 expression (14). These results were confirmed in an independent trial in which engraftment of the CTLs, as measured by an elevated frequency of circulating T cells able to bind tetramers loaded with MART-1 peptides, was detectable up to two weeks after T cell transfer in all patients, with a maximal frequency of 2% of the total CD8+ T cells (15). Despite this high level of engraftment in all patients, only 3 of 11 patients had clinical antitumor responses, and a selective loss of MART-1 expression in lymph node metastases in 2 of 2 evaluated patients was observed (15). Therefore, perhaps the most worrisome issue revealed with CTL transfers is the emergence of antigen escape variants, which seems to be more common in human tumors than in mouse syngeneic tumor models (16, 17). However, preliminary results have indicated that CTL transfers in patients with melanoma might have a vaccine-like effect, inducing epitope spreading, in that the antitumor response correlated with the detection of T cell clones with higher avidity for the tumor antigen and with a broader tumor antigen–specific repertoire than was detected before treatment (18). Therefore, it is possible that the problem of antigen escape variants can be addressed by enhancing the immune response to include a broad tumor antigen–specific T cell repertoire, either by increasing the efficiency of epitope spreading or by infusing CTL clones with multiple antigenic specificities.

TIL therapy

Adoptive transfer therapy with TILs requires the isolation of T cells from fresh patient biopsy specimens and the progressive selection

Nonstandard abbreviations used: DLI, donor lymphocyte infusion; GVHD, graft-versus-host disease; HSV-TK, herpes simplex virus thymidine kinase; MART-1, melanoma-associated antigen recognized by T cells 1; TIL, tumor-infiltrating lymphocyte.

Conflict of interest: C.H. June receives income from BD Biosciences, Cell Genesys, CellDex Therapeutics, Maxyte, and AVEO Pharmaceuticals Inc. and research support from BD Biosciences, GLaxoSmithKline, and Sargamso Biosciences. He also has patents and patent applications in the fields of adoptive T cell therapy and immuno-suppression.

Citation for this article: J Clin Invest. 117:1466–1476 (2007). doi:10.1172/JCI32446.
of tumor-specific T cells ex vivo using high levels of IL-2 and various cell culture approaches (Figure 1). The adoptive transfer of these cells showed promise in preclinical models (19), but clinical experiences, with perhaps one exception (20), were almost uniformly disappointing (21–23). However, recent studies at the National Cancer Institute suggest that prior host conditioning with chemotherapy increases the response to adoptive immunotherapy with TILs (7, 24). When 13 patients with progressive metastatic melanoma were given cyclophosphamide and fludarabine, a drug regimen that is immunosuppressive but does not have anti-melanoma efficacy, 6 patients had partial responses as judged by Response Evaluation Criteria in Solid Tumors (RECIST; ref. 25), and 4 others had mixed responses, i.e., some of their tumors regressed but others remained (7). This approximately 50% objective response rate was confirmed in a subsequent report from the same group (24). Importantly, the TILs showed prolonged engraftment compared with TILs transfused to patients without prior treatment with these chemotherapeutics, and the levels of engraftment correlated with the clinical responses. Indeed, concomitant host immunosuppression seems to be important because only 34% of patients with melanoma who were treated with TIL administration and high-dose IL-2 and who received no prior chemotherapeutic conditioning therapy to induce lymphodepletion achieved objective clinical responses in trials previous to the incorporation of host lymphodepletion (21); most of the responses were transient, and the patients had limited persistence of the transferred cells in those trials. Adverse effects in the lymphodepletion trial included opportunistic infections and the frequent induction of vitiligo and uveitis, presumably due to autoimmunity. However, at this point, the results are difficult to interpret, as the ability to successfully generate TILs for therapy could be a predictive biomarker of a more favorable clinical outcome (4, 5, 26, 27). Therefore, in the absence of a randomized clinical trial it is not possible to determine how much lymphoablative chemotherapy, high-dose IL-2 administration, and TIL therapy contributed to the promising results in these recent trials (7, 24). If it is confirmed that lymphodepletion augments TIL efficacy, the results from recent trials indicate that induction of immunosuppression in the host improves the antitumor efficacy of adoptive TIL therapy. Pre-clinical models suggest that the concomitant transfer of autologous HSCs might have an additional effect in promoting the antitumor efficacy of adoptively transferred T cells (28). This would suggest that a combination of autologous HSC transplant approaches with adoptive therapy could have improved clinical results and may explain some reports of autologous graft-versus-host disease (GVHD) (29).

Technical issues with producing tumor-specific T cells currently present a formidable barrier to conducting randomized clinical trials using TILs. Only 30%–40% of biopsy specimens yield satisfactory T cell populations, and the process is labor and time intensive, requir-
ing about 6 weeks to produce the T cells for infusion (30). Therefore, randomized trials based on rigorous intent-to-treat analysis design (in which all data from all patients are included in the data analysis and any patients who are discontinued or otherwise nonevaluable are considered to be treatment failures) cannot be performed using currently available tissue culture technologies, and the trials reported to date have been performed based on an ad hoc, as-treated analysis plan. Furthermore, nearly all clinical experience with TILs has been with patients with melanoma because of the ready surgical availability of tumor biopsy tissue. However, should technical limitations of current tissue culture approaches be overcome, the recent studies indicating that the presence of TILs correlated positively with survival in ovarian and colorectal cancer (4, 5) could extend the impact of this promising therapeutic approach to other commonly encountered epithelial cancers.

Combination approaches using vaccines and adoptive T cell transfer

Due to the limited time window and practical constraints imposed by large tumor masses (because immediate tumor regression is desired), therapy is superior to therapeutic vaccination as a single therapeutic modality (31, 32), and therefore, as a corollary, the strategy of therapeutic tumor vaccination of cancer patients is likely to succeed mainly in the setting of minimal residual disease (33). In mice, adoptive T cell therapy enhances the effects of therapeutic vaccines (34, 35), and this combined approach in the setting of lymphopenia results in a further enhancement of tumor immunity compared with combined treatment in lymphoreplete hosts (36, 37). In humans with myeloma, idiotypic vaccination of sibling donors with the unique tumor-specific Ig produced by the patient’s myeloma cells followed by adoptive transfer in the setting of allogeneic stem cell transplantation can result in the induction of potent antitumor immunity (38). However, although theoretically attractive, there is not yet extensive data in humans to demonstrate the efficacy of a combined vaccine and adoptive T cell transfer approach in the autologous setting.

Two phase I clinical trials using autologous activated T cells transplanted for hematologic malignancies in patients have been reported. In the first trial (39), patients with relapsed or chemotherapy refractory non-Hodgkin lymphoma were given a CD34+ HSC transplant followed by infusion of autologous T cells expanded ex vivo with CD3- and CD28-specific antibodies (40). Infusion of the autologous costimulated T cells resulted in a rapid reconstitution of lymphocyte numbers. Importantly, the expanded cells were functionally superior to those obtained directly from the patients, as determined by their ability to produce IFN-γ when stimulated with tumor cells in vitro. In a second randomized trial, the feasibility was tested of pre-transplant immunization and adoptive transfer of vaccine-primed T cells in the setting of autologous transplantation for multiple myeloma (41). Patients were vaccinated with Prevnar, the heptavalent pneumococcal conjugate vaccine (PCV), and two weeks later T cells were harvested and expanded in

Figure 2

Suicide T cell therapy using adoptively transferred T cells. T cells can be engineered to express conditional suicide switches so that the T cells die when a drug is administered that activates the switch and causes apoptosis. Suicide constructs have been incorporated into allogeneic T cells that can be ablated in the event of GVHD and into autologous T cells that can be ablated in the event of toxicity or uncontrolled T cell proliferation.
Shu and Chang have developed an alternative vaccine adoptive transfer approach that could circumvent some of the limitations posed by adoptive transfer using TILs. They and others have shown in mice that tumor-draining lymph nodes harbor T cells that are not able to mediate tumor rejection in adoptive transfer experiments (42, 43). By contrast, if the draining lymph node cells are activated in vitro by various culture approaches, the cells are able to mediate tumor rejection after adoptive transfer (44). In a further study (45), T cells were isolated from vaccine-primed lymph nodes obtained from patients with melanoma, renal cell carcinoma, and head and neck cancer. In the absence of APCs, activation with CD3- and CD28-specific antibodies greatly enhanced subsequent T cell expansion in response to IL-2 compared with activation with CD3-specific antibody alone (45). Based on these and other preclinical data, Chang and coworkers carried out a phase I clinical trial in patients with either advanced melanoma or renal cell carcinoma (46). Patients were vaccinated with irradiated autologous tumor cells and draining lymph nodes were harvested 7–10 days later and the vaccine-primed T cells cultured and infused (Figure 1). Among the 11 patients with melanoma, 1 had a partial tumor regression, and among the 12 patients with renal cell carcinoma, there were 2 complete and 2 partial tumor regressions (46), suggesting that there might be some clinical benefit to this adoptive transfer approach to boost the clinical efficacy of therapeutic cancer vaccines.

**Engineered T cells**

Genetic modification of T cells to engineer improved antitumor effects and enhanced immune reconstitution of immunosuppressed patients is an attractive strategy in many settings (47). In patients with congenital and acquired immunodeficiency, genetically modified T cells have been shown to persist for years in humans following adoptive transfer (48, 49), which indicates that the general approach is feasible. A potential safety concern when infusing individuals with engineered T cells is one that arose with genetically engineered HSCs (50), when viral insertional mutagenesis was shown to cause cellular transformation. Although there is little clinical experience with engineered T cells for cancer therapy, it is notable that clinical trials to date using cells engineered to express suicide molecules have indicated that the approach is safe.

**T cells engineered to express suicide molecules.** Severe and potentially lethal GVHD represents a frequent complication of allogeneic immunotherapy and donor lymphocyte infusion (DLI). The promising results with DLI have created increased interest in developing T cells with an inducible suicide phenotype (Figure 2). Expression of...
and colleagues infused allogeneic donor lymphocytes engineered to immunogenicity to the transfused cells, leading to their impaired survival. Lamers and colleagues recently tested T cells expressing a T body receptor specific for a folate-binding protein that is present on ovarian carcinoma cells indicated that the approach was safe, but poor expression and persistence of the transgene encoding the T body receptor were observed in vivo (59). Similarly, a pilot test in children with neuroblastoma treated with autologous T cells retargeted for a tumor-associated adhesion molecule has indicated that the approach is safe but was limited by poor persistence of the T cells (60). Lammers and colleagues recently tested T cells expressing a T body receptor specific for carbonic anhydrase IX, an antigen present on the surface of clear cell renal cell carcinoma (61). They observed an unexpected serious hepatic toxicity in several patients.

Table 1
Strategies to augment adoptive T cell therapy

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjuvants to promote maintenance of Th1 cell function, e.g., endotoxin administration to humans</td>
<td>111</td>
</tr>
<tr>
<td>Antibody infusions to prevent CTLA-4 inhibitory effects</td>
<td>112</td>
</tr>
<tr>
<td>Antibody infusions to block PD-L1–PD-1 interactions and rejuvenate exhausted T cells</td>
<td>113</td>
</tr>
<tr>
<td>Antibody infusions to enhance 4-1BB signals</td>
<td>114</td>
</tr>
<tr>
<td>Bispecific antibodies to “arm” T cells to facilitate trafficking and cytotoxicity</td>
<td>115, 116</td>
</tr>
<tr>
<td>Cytokine administration, for example, IL-2, IL-7, IL-12, IL-15, or IL-21</td>
<td>74</td>
</tr>
<tr>
<td>Cytokine antagonists, e.g., TGF-β blockade or inhibition</td>
<td>117</td>
</tr>
<tr>
<td>CD4+ Th cell infusion to sustain CTL function</td>
<td>118</td>
</tr>
<tr>
<td>Host lymphodepletion</td>
<td>102, 119</td>
</tr>
<tr>
<td>Host Treg depletion or inhibition</td>
<td>120</td>
</tr>
<tr>
<td>Nonmyeloablative stem cell transplantation to facilitate allogeneic T cell transfers</td>
<td>121, 122</td>
</tr>
<tr>
<td>Tumor bed manipulation via several approaches</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>123</td>
</tr>
<tr>
<td>Chemokine expression in tumor bed to promote lymphocyte trafficking</td>
<td>124</td>
</tr>
<tr>
<td>Cryoablation</td>
<td>125</td>
</tr>
<tr>
<td>Phosphodiesterase-5 inhibition</td>
<td>126</td>
</tr>
<tr>
<td>Tumor stroma and microvasculature: sensitization to induce T cell trafficking and cytotoxicity</td>
<td>75, 127</td>
</tr>
<tr>
<td>Vaccine therapy</td>
<td>41, 128</td>
</tr>
</tbody>
</table>

CTLA-4, cytotoxic T-cell–associated gene 4; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1.

Herpes simplex virus thymidine kinase (HSV-TK) in T cells provides a means of ablating transduced T cells in vivo by the administration of ganciclovir or ganciclovir (51). Using this strategy, Bordignon and colleagues infused allogeneic donor lymphocytes engineered to express HSV-TK into 8 patients with refractory hematologic malignancies who had suffered complications such as cancer relapse or virus-induced lymphomas after receiving allogeneic bone marrow transplants from the donor of the allogeneic lymphocytes (52). The lymphocytes survived for up to a year, and complete or partial tumor remission in five of the eight patients was achieved. Tumor regression coincided with onset of GVHD, and in most cases, GVHD was abrogated when ganciclovir was administered. A recent phase II clinical trial has confirmed and extended these results to further demonstrate the safety and feasibility of adoptive transfer of suicide gene–transduced donor T cells (53). Previously, transplantation of haploidentical HSCs had only been possible with T cell depletion of the allogeneic stem cell graft to prevent GVHD, but this resulted in profound immunodeficiency following transplant. The HSV-TK approach seems to promote immune reconstitution and preserve the antitumor effects of the adoptively transferred T cells in immunosuppressed recipients. It is possible that the first form of adoptive therapy with engineered T cells to enter clinical practice will be the use of allogeneic T cells engineered to have a conditional suicide switch, as a phase III clinical trial is planned to test this approach in the setting of haploidentical HSC transplantation.

The principal concern with the HSV-TK approach has been that it would generate potent HSV-TK–specific immune responses, thereby inducing elimination of the adoptively transferred T cells independently of ganciclovir administration. For example, others have found that humans efficiently reject cells engineered to express HSV-TK or similar constructs (54, 55). Therefore, under conditions in which the host is not as profoundly immunosuppressed, such as in the case of haploidentical transplantation, HSV-TK might confer immunogenicity to the transfused cells, leading to their impaired survival and the inability to retreat a patient with a DLI of cells engineered to express HSV-TK should the tumor recur. Future development of vectors that encode less immunogenic proteins but are able to confer even higher ganciclovir sensitivity to transduced human T cells is required to extend this approach to immunocompetent hosts. Recently, investigators have developed suicide systems comprised of fusion proteins containing a human FAS or caspase death domain and a modified FK506-binding protein (FKBP) (56, 57). These approaches have the advantage that the suicide switches are expected to be nonimmunogenic because they are based on endogenous proteins. T cells expressing these modified chimeric proteins are induced to undergo apoptosis when exposed to a drug that dimerizes the modified FKBP (Figure 2).

T cells engineered to express tumor antigen–specific receptors. A principal limitation of adoptive T cell therapy for some tumors is that the tumors are poorly antigenic; therefore, neither T cells with high avidity for tumor-specific antigens, nor T cells with the desired specificity remain in the patient following chemotherapy. Two strategies to overcome this limitation are now being tested in the clinic (Figure 3). One approach has been to endow T cells with novel receptors by introduction of “T bodies,” chimeric receptors that have antibody-based external receptor structures and cytosolic domains that encode signal transduction modules of the T cell receptor (58). These constructs can function to retarget T cells in vitro in an MHCrestricted manner to attack the tumor while retaining MHCrestricted specificity for the endogenous TCR. Three pilot clinical trials have recently been reported. A trial that tested T cells expressing a T body receptor specific for a folate-binding protein that is present on ovarian carcinoma cells indicated that the approach was safe, but poor expression and persistence of the transgene encoding the T body receptor were observed in vivo (59). Similarly, a pilot test in children with neuroblastoma treated with autologous T cells retargeted for a tumor-associated adhesion molecule has indicated that the approach is safe but was limited by poor persistence of the T cells (60). Lammers and colleagues recently tested T cells expressing a T body receptor specific for carbonic anhydrase IX, an antigen present on the surface of clear cell renal cell carcinoma (61). They observed an unexpected serious hepatic toxicity in several patients.

The Journal of Clinical Investigation
http://www.jci.org Volume 117 Number 6 June 2007
within a week of T cell infusion that seemed to be due to carbonic anhydrase IX expression in the biliary tract. If confirmed, this would indicate that engineered T cells can traffic to and exert effector function at sites of antigen expression in vivo. Furthermore, this study indicates that the targets of chimeric antigen receptors must be carefully chosen to avoid unwanted adverse effects, or that additional safety features, such as suicide switches, need to be incorporated into the vectors driving the expression of the chimeric receptor. In several of the patients in the studies described above, the engineered cell persisted for several days to weeks before elimination by host immune responses (59–61), indicating that a technical challenge for this approach is to prevent a host immune response from eliminating the adaptively transferred cells. The other major issues with the approach currently involve improving receptor design by optimizing the ligand-binding domain and by trying to incorporate costimulatory signaling domains into the signaling module (62). The former issue is important because the avidity of the ligand-binding domain must be tuned to afford specificity for the tumor cells and yet permit disengagement from the target so that the redirected T cells can be “serial killers.” The later issue is important to ensure long-term survival of the T cells so that the proper costimulatory signals can be delivered upon tumor recognition, thereby avoiding the induction of anergy or apoptosis (63) and by potentially increasing the resistance of the T cells to the immunotoxic effects of the tumor microenvironment (64).

T cells are also being transduced to express natural αβTCR heterodimers of known specificity and avidity for tumor antigens (65). In the first clinical trial using this approach, T cells were engineered to express a TCR specific for glycoprotein 100 (gp100), and lymphodepleted patients with melanoma were given a single infusion of these engineered T cells followed by an infusion of IL-2 (66). A concern with this approach has been that it might generate additional, novel receptor specificities by pairing of the transgenes with the endogenous TCR chains. It is encouraging that no toxicity was observed in the pilot trial, and promising persistence of the engineered T cells was observed in some of the patients. However, one issue that arose was low cell-surface levels of expression of the gp100-specific TCR, which would be expected to lower the avidity of the TCR and therefore minimize effector functions. Another general limitation of this approach for humans is that each TCR is specific for a given

### Table 2
Adoptive transfer therapy for cancer: randomized clinical trials

<table>
<thead>
<tr>
<th>Disease</th>
<th>Trial description</th>
<th>Trial outcome</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastric cancer</td>
<td>Patients (n = 44) were randomized to receive TILs administered i.p. plus chemotherapy or chemotherapy alone.</td>
<td>Survival was 11.5 months in TIL plus chemotherapy group and 8.3 months in chemotherapy only group (P &lt; 0.05). No difference in objective response rates.</td>
<td>20</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>Surgically resected patients (n = 150) were randomized to receive no additional treatment or an adoptive transfer of peripheral blood T cells activated in vitro with CD3-specific antibody and IL-2.</td>
<td>Longer tumor progression–free survival (P = 0.01) and longer time to first recurrence (P = 0.008) in the immunotherapy arm, with a reduction in risk of tumor recurrence by 41%, but overall survival did not differ (P = 0.09).</td>
<td>48</td>
</tr>
<tr>
<td>Renal cancer and melanoma</td>
<td>Patients with renal cancer (n = 97) and melanoma (n = 54) were randomized to receive either IL-2 alone or IL-2 plus adoptively transferred LAKs.</td>
<td>Trend toward increased survival when IL-2 was given with LAKs in patients with melanoma (P = 0.09), but no trend was observed for patients with renal cancer.</td>
<td>129</td>
</tr>
<tr>
<td>Renal cancer</td>
<td>Patients with metastatic renal-cell carcinoma (n = 90) were randomized to receive monthly for 6 months an infusion of autologous PBLs activated with CD3-specific antibody and conditioned medium plus oral cimetidine or cimetidine alone.</td>
<td>Positive results were reported initially, but later trials did not confirm the earlier results.</td>
<td>130</td>
</tr>
<tr>
<td>Renal cancer</td>
<td>Phase III clinical trial randomized patients to receive continuous i.v. rIL-2 alone (n = 36) or rIL-2 and adoptively transferred LAK cells (n = 35).</td>
<td>The addition of LAK cells did not improve the response rate, as there were no differences between the arms with regard to response (P = 0.61) and survival (P = 0.67).</td>
<td>131</td>
</tr>
<tr>
<td>Renal cancer</td>
<td>Phase III clinical trial of patients (n = 178) who had undergone radical nephrectomy and were randomized to receive TILs in combination with low-dose IL-2 or IL-2 alone.</td>
<td>Intent-to-treat analysis demonstrated that TILs did not improve response rate or survival in patients treated with low-dose rIL-2 after nephrectomy.</td>
<td>22</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>Phase II randomized clinical trial tested the efficacy of TIL plus rIL-2 infusions compared with conventional therapy in patients (n = 113) with Stage II, IIIa, or IIIb NSCLC.</td>
<td>Improved three-year survival (P &lt; 0.05) for patients given TIL plus rIL-2 therapy. Median survival was 22.4 and 14.1 months in the TIL plus rIL-2 and control groups, respectively.</td>
<td>96</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Patients with stage III melanoma were randomized (n = 88) to receive TIL plus rIL-2 or rIL-2 alone.</td>
<td>There was no difference in disease-free survival or overall survival. Post-hoc subgroup analysis revealed a subgroup effect: in patients with only one involved lymph node, the estimated relapse rate was significantly lower (P = 0.028) and the overall survival was significantly increased (P = 0.039) in the TIL plus IL-2 arm compared with the IL-2–only arm.</td>
<td>23</td>
</tr>
</tbody>
</table>

LAK, lymphokine-activated killer cell; NSCLC, non–small cell lung cancer; rIL-2, recombinant IL-2.
peptide-MHC complex, such that each vector would only be useful for patients that shared both MHC alleles and tumor antigens.

*T cells engineered for enhanced survival.* A limitation to adoptive transfer of CTLs is that they have short-term persistence in the host in the absence of antigen-specific Th cells and/or cytokine infusions. Greenberg and coworkers have transduced human CTLs with chimeric GM-CSF–IL-2 receptors that deliver an IL-2 signal when they bind GM-CSF (67). Stimulation of the CTLs with antigen caused GM-CSF secretion and resulted in an autocrine growth loop such that the CTL clones proliferated in the absence of exogenous cytokines. This type of genetic modification has the potential to increase the circulating half-life of the CTLs and, by extension, the efficacy of these ex vivo–expanded cells. A related strategy to rejuvenate T cell function is to engineer T cells to ectopically express CD28 (68) or the catalytic subunit of telomerase (69). To rejuvenate T cell function through various cell-autonomous mechanisms, as discussed above. In addition, T cells can be engineered for resistance to cell extrinsic forms of immunosuppression such as those mediated by TGF-β and Tregs (64, 79). Therefore, as with other forms of immunotherapy, it is probable that the ultimate clinical application of adoptive T cell transfer will employ combinatorial approaches (80).

**Strategies to augment the efficacy of adoptively transferred T cells**

There are a number of strategies that might augment the function of adoptively transferred T cells (Table 1). The efficacy of adoptive transfer is enhanced by other immunotherapies such as cytokine administration (74), and in some circumstances, by standard cytotoxic chemotherapy and radiation (75, 76). Recent studies indicate that the choice of chemotherapy might be more important than was previously realized, as some cytotoxic agents render tumor cells more immunogenic than others, independent of the fractional killing effect of the drug (77, 78). Genetic engineering of T cells has the potential to augment function through various cell autonomous mechanisms, as discussed above. In addition, T cells can be engineered for resistance to cell extrinsic forms of immunosuppression such as those mediated by TGF-β and Tregs (64, 79). Therefore, as with other forms of immunotherapy, it is probable that the ultimate clinical application of adoptive T cell transfer will employ combinatorial approaches (80).

**Clinical trials**

A premise of this Review is that clinical trials of adoptive T cell transfer based on a sufficient understanding of lymphocyte and cancer biology have only begun in recent years. Nevertheless, lessons can be learned from previous trials that failed to achieve the expected clinical efficacy. In addition, issues related to the clinical translation of adoptive T cell transfer therapy are discussed below, with an emphasis on dose and scheduling issues, potential toxicities, and the optimal antigens to target with adoptively transferred T cells.

**Status.** Pilot clinical trials of adoptive T cell immunotherapy were initiated in cancer soon after the discovery of IL-2, which enabled the large scale culture of T cells for the first time (81). However, until recently, the clinical trials have been carried out with populations of cells that we now know were rendered tolerant or “anergic”, senescent, or immunogenic. The major criticism of the field has been that, until recently, no randomized clinical trials had demonstrated that adoptive T cell transfer approaches were efficacious (Table 2). The adoptive transfer of EBV-specific T cell lines and CTLs for the therapy of EBV-induced lymphomas is perhaps the best demonstration of clinically efficacious adoptive T cell therapy (82, 83). However, the EBV-induced lymphomas that occur in immunosuppressed patients are a “disappearing disease,” as advances in treatment to use a CD20-specific antibody (Rituximab) have drastically reduced the incidence of this once not uncommon disorder. Therefore, in the case of EBV-associated malignancies, a randomized efficacy trial is not likely to occur. To date, there has only been one randomized clinical trial that had a positive outcome; a rigorous intent-to-treat analysis of adoptive transfer trial in cancer has been in the adjuvant setting for hepatocellular carcinoma following surgical resection of the primary tumor (84). In that study, autologous peripheral blood T cells were cultured with CD3-specific antibody and IL-2, and the risk of cancer recurrence was reduced by 41% in the group treated with surgery and a T cell infusion compared with the group treated with surgery only. However, this trial remains unconfirmed, and the mechanism of the antitumor effect remains unknown. It is critical to learn whether a specific antitumor effect or an antiviral response directed to HCV, the agent often implicated in the pathogenesis of hepatocellular carcinoma (85), was involved in the protective effect. It is also conceivable that other effects, such as a reduction in the suppressive effect of Tregs, could have occurred in this trial as well. These are important lessons to learn, as hepatocellular carcinoma is the third leading cause of cancer-related deaths worldwide.

**Dose and scheduling issues.** Information on the dose and schedule dependence of adoptively transferred cells is widely scattered in the literature, and from this literature one concludes that there is no standardized dosage system. There is, however, evidence from animal models (in nonlymphopenic hosts) suggesting that multiple doses of adoptively transferred T cells are superior to a single infusion of T cells (86). Doses of adoptively transferred cells are usually reported as the total number of viable cells administered or as the total number of viable cells administered per kilogram of body weight or per square meter of body surface area. However, total endogenous lymphocyte numbers do not correlate well with body surface area but rather display a strong inverse correlation with age. Other variables add to the complexity, particularly the fact that, in the case of T cells or other adoptively transferred cells with high replicative potential, the infused dose might not relate well to the steady-state number of cells that engraff and persist. Therefore, dose considerations are more complex than in other areas of transfusion medicine, where, for example, the maximal
level of transfused red cells or platelets occurs immediately following infusion. In our studies of adoptively transferred autologous CD4+ T cells, we often find that the number of cells in the host peaks two weeks after infusion of the cells (87). This is because the engraftment potential and the replicative potential of the infused cells depends on complex host variables such as the number of niches available in the host for engraftment, and the antigenic stimulus for clonal expansion or deletion. In most rodent tumor models, T cell proliferation in the host after transfer is obligatory for therapeutic efficacy (reviewed in ref. 88), and with rare exceptions (89), this is presumed to also be required in humans.

Cytokines given to the host can also have a major impact on the persistence of adoptively transferred T cells. Others have found that the persistence of adoptively transferred human CD8+ T cells is enhanced by coadministration of IL-2 (13). However, we have found that when autologous human CD4+ T and CD8+ T cells are given in combination, persistence is not increased by concomitant IL-2 therapy (49). Finally, recent studies show that IL-2 can induce the proliferation and maintenance of effector CD8+ T cells but might actually deplete memory T cells and increase the number of Tregs (90). By contrast, IL-15 and IL-7 seem to select for the persistence of memory CD8+ T cells and might decrease the ratio of Tregs to effector T cells (91).

Striking schedule-dependent increases in efficacy and the frequency of adverse effects from adoptively transferred cells have been reported when T cell infusions are given to lymphopenic hosts (7). Many studies in rodent tumor models show that the coadministration of cytotoxic therapy can enhance the effects of adoptively transferred cells (92). Cyclophosphamide and/or fludarabine are generally administered to the host several days before the adoptively transferred T cells (7, 88). The drugs have multiple effects that seem to promote the antitumor effects of the adoptively transferred T cells. There is evidence for numerous effects, including killing of host Tregs that suppress antitumor immune responses; creating "space" in the host so that the adoptively transferred T cells can engraft (93); and perhaps enhancing cross-priming of tumor antigens. Curti and colleagues (94), have studied the optimal time to harvest autologous CD4+ T cells in relation to the timing of cyclophosphamide administration in patients with advanced cancers. T cells were harvested at steady state or either when on the decline or recovery from the cyclophosphamide-induced leukopenia, and Curti et al. found the greatest in vivo CD4+ T cell expansion following infusion when cells were harvested as patients entered the cyclophosphamide-induced nadir (94). In a study of patients with stage III non–small cell lung cancer, investigators tested the sequence of adoptive therapy with autologous TIL and IL-2 followed by standard chemotherapy and radiotherapy, and perhaps not surprisingly, they found that immunotherapy followed by chemotherapy was not effective (95); the reverse schedule of therapy was not tested as a concurrent comparison in this trial, however previous randomized trials from this group had demonstrated clinical activity when chemotherapy was followed by immunotherapy (96).

Toxicity issues. Many types of adverse events have been reported following infusion of human autologous or allogeneic lymphocytes. The toxicities can be classified as those that result from extrinsic factors present in the culture process, those resulting from accompanying cytokines that can be co-infused with the cells, and those that result from the cells themselves. The spectrum of the third form of adverse effects is still being defined and for the moment seems to be related to whether the cell product is genetically engineered. For cell products that have not been genetically engineered, the adverse effects are limited and are similar to those observed with therapeutic vaccines. Cytokine release syndrome, retinitis, iritis, hepatitis, autoimmune thyroiditis with hypothyroidism, and vitiligo occur following autologous T cell infusions (7, 14, 61, 97). Respiratory obstruction has been reported following CTL infusion for EBV-related lymphomas (82). This is probably due to a T cell–induced inflammatory response that results in tumor edema and necrosis. Effector functions of infused T cells can be expected to include tissue damage similar to that encountered in T cell–mediated autoimmune diseases. In the case of allogeneic lymphocyte infusions, GVHD and bone marrow aplasia can occur (98). Theoretic toxicities associated with T cell transfer also include leukemia or lymphoma if transformation is induced consequent to the in vitro culture process. However, in human trials involving genetically modified T cells, no cases of malignant transformation of the infused T cells have been reported to date.

Finally, dose- and schedule-dependent effects have been observed with allogeneic T cell infusions vis-à-vis the induction of GVHD. Early studies showed that the infusion of donor T cells soon after a myeloablative transplant conditioning regimen resulted in the marked augmentation of acute GVHD (99). It has been well established by the work of O'Reilly and colleagues that the initial dose of infused T cells in the setting of allogeneic bone marrow transplantation has a major effect on the incidence and severity of acute GVHD (98). However, it has only been recently appreciated that donor T cells can be infused with relative freedom from acute GVHD in the setting of nonmyeloablative stem cell transplantation (100). Studies show that, in the steady-state setting of relapsed chronic myelogenous leukemia following allogeneic HSC transplantation, infusions of resting donor T cells result in a decreased incidence of acute GVHD when given by dose fractionation, starting with low doses of donor cells and escalating subsequent doses as required (101). Some of these effects might be related to recent findings in mice that effector CD8+ T cell function and presumably toxicity are related to concomitant HSC infusion (28).

Tregs. Cancer patients have increased numbers and function of CD4+CD25+ Tregs at the tumor site (8). The in vivo depletion of Tregs enhances the antitumor effects of adoptively transferred effector T cells (102). On the other hand, preclinical models show that the adoptive transfer of Tregs was able to prevent GVHD while preserving graft versus tumor activity (103). Recently, we and others have developed ex vivo culture conditions that should permit pilot trials of Treg adoptive immunotherapy for the prevention or therapy of GVHD (104, 105).

Targeting issues: public versus private antigen controversy. There is controversy in the choice of antigen to target with adoptively transferred T cells. For the past several decades, shared (also known as “public”) tumor-associated antigens have been the favored target of various immunotherapy strategies. This approach has been based largely on melanoma and has been led by a study of the CTLs obtained from a patient with melanoma (106). Most of the antigens targeted by T cells obtained from patients with regressing melanoma had expression that was shared between tumor cells and their normal cell counterparts. Implications from these shared tumor–associated antigens were that, in order to achieve tumor eradication it was necessary to expect tissue-specific toxicity, such as vitiligo in the case of melanoma and prostatitis in the case of prostate cancer. Therefore, the concept of “dispensable tissues"
arose (107), meaning that in the case of some tumors, damage or destruction of normal tissue would be an accepted and expected potential toxicity. Because expression of these antigens was also shared between different individuals, the preparation of patient-independent vaccine preparations would be possible. In theory however, patient-specific (also known as “private”) tumor antigens that arise from mutations could also serve as a source of tumor-specific targets. Strategies to target patient- and tumor-specific mutations have been proposed but have not received much attention in the field (108, 109). This situation is likely to change given the striking finding that common tumors such as breast and colon cancer have, on average, about 90 mutations per tumor that generate amino acid substitutions (110), a figure much higher than was previously thought. These findings have major implications for cancer immunotherapy, as a strategy that is directed against patient- and tumor-specific antigens is likely to have fewer off target effects. In addition, it might be possible to generate T cells with much higher avidity for the tumor target, since the TCR repertoire to these putative tumor-specific antigens is not expected to have been subject to editing by thymic tolerance mechanisms. By contrast, strategies targeting shared tumor-associated antigens are likely to have fewer off target effects. In addition, it might be possible to generate T cells that are specifically targeted to low-avidity antigens that are generally of low avidity and susceptible to immunologic tolerance.

Conclusions
Adaptive T cell therapy is the ultimate challenge to implementation of personalized medicine. To be commercially viable, adoptive T cell therapy has to be clinically effective, scalable, reproducibly manufactured, and appropriately priced and marketed. Will therapy be delivered using a blood banking model or by centralizing manufacturing plants? It is probable that engineered T cell therapies will require stringent manufacturing controls that favor centralized manufacturing plants, whereas some forms of manufacturing for natural T cell therapies could be carried out at tertiary care medical centers. The anticipated approval of a therapeutic cancer vaccine for prostate cancer based on autologous DCs is on the near horizon, which suggests that many of these challenges can be addressed. However the major challenge facing the field at present is to conduct randomized clinical trials demonstrating sufficient clinical benefit to justify the logistics and expense of customized cellular therapies.

Acknowledgments
The author thanks Bruce Levine, James Riley, Richard Carroll, Robert Vonderheide, and George Coukos for helpful discussions and Coral Haas for administrative help. The author is grateful for support of these studies by NIH grants SRO1CA105216, 1RO1CA104679, and S500CA083638, the Leukemia and Lymphoma Society, and the Alliance for Cancer Gene Therapy. The author is grateful for advice from many colleagues and collaborators over the years and, due to constraints on references, apologizes for the inability to cite all relevant references.

Address correspondence to: Carl H. June, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104-6160, USA. Phone: (215) 573-5745; Fax: (215) 573-8590; E-mail: cjune@mail.med.upenn.edu.

70. Waller, E.K., et al. 1999. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow